Can Obama Help Vete...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$13.35 -0.79 | -5.59%
06/01/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 54.34M | 63.50M | 125.30M | 24.05M |
| Receivables | 6.94M | 0.00 | 20.00M | 24.35M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 107.62M | 99.54M | 190.74M | 127.08M |
| Property, Plant & Equipment, Gross | 14.11M | 13.29M | 12.74M | 12.31M |
| Accumulated Depreciation & Depletion | 11.10M | 9.31M | 7.27M | 5.36M |
| Property, Plant & Equipment, Net | 3.01M | 3.98M | 5.47M | 6.95M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.48M | 21.06M | 9.50M | 27.80M |
| Total Non-Current Assets | 11.38M | 31.84M | 20.77M | 40.64M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 119.00M | 131.39M | 211.51M | 167.72M |
| Accounts Payable | 941.00K | 6.28M | 464.00K | 614.00K |
| Short Term Debt | 0.00 | 0.00 | 9.19M | 7.00K |
| Other Current Liabilities | 2.00M | 0.00 | 0.00 | 163.00K |
| Total Current Liabilities | 19.77M | 47.62M | 133.72M | 93.35M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 9.42M | 0.00 |
| Other Non-Current Liabilities | 23.23M | 11.22M | 1.46M | 65.38M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 23.23M | 11.22M | 10.88M | 65.38M |
| Total Liabilities | 43.00M | 58.84M | 144.60M | 158.74M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 76.00M | 72.55M | 66.90M | 8.98M |
| Common Par | 36.00K | 25.00K | 24.00K | 15.00K |
| Additional Paid In Capital | 526.24M | 461.42M | 441.80M | 306.83M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -450.30M | -388.93M | -374.86M | -298.33M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 18.00K | 31.00K | -55.00K | 469.00K |
| Total Capitalization | 76.00M | 72.55M | 66.90M | 8.98M |
| Total Equity | 76.00M | 72.55M | 66.90M | 8.98M |
| Total Liabilities & Stock Equity | 119.00M | 131.39M | 211.51M | 167.72M |
| Total Common Shares Outstanding | 35.73M | 25.45M | 23.87M | 15.30M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 33.29M | 24.49M | 18.86M | 15.22M |
| Diluted Weighted Shares Outstanding | 33.29M | 24.49M | 18.86M | 15.22M |
| Number of Employees | 130 | 140 | 143 | 147 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with AFFY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserBurrdee
- ContributorStocks At New 52-Week Highs...
- Usersimulator
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
Latest AFFY Headlines from TheStreet
- 8 Stocks Rising on Monster Volume 04.02.12 | 01:04 pm
- Biotech Stock Mailbag: MAP Pharma, Affymax 03.30.12 | 05:03 am
- 8 Stocks Rising on Huge Volume 03.23.12 | 02:03 pm
- Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest 03.23.12 | 05:03 am
- The Next Big Thing in Biotech: FDA Decisions
03.23.12 | 05:03 am - Biotech Stock Chat: Recap 03.15.12 | 11:03 am
- 5 Stocks Ready to Soar on Bullish Earnings 03.13.12 | 06:03 am
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- 6 Stocks at New 52-Week Highs 02.14.12 | 02:02 pm
Press Releases for AFFY
- Affymax To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 06.01.12 | 08:06 am
- Affymax Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 04:05 pm
- Affymax And Takeda Announce Centers For Medicare And Medicaid Services Has Assigned A Q-Code For OMONTYS® (Peginesatide) Injection - Business Wire 04.13.12 | 08:04 am
- Affymax Receives A $50 Million Milestone Payment For U.S. Approval Of OMONTYS® (peginesatide) Injection - Business Wire 04.09.12 | 04:04 pm
- Affymax And Takeda Announce FDA Approval Of OMONTYS® (Peginesatide) Injection For The Treatment Of Anemia Due To Chronic Kidney Disease (CKD) In Adult Patients On Dialysis - Business Wire 03.27.12 | 02:03 pm
- Affymax® Reports Year End 2011 Financial Results - Business Wire 03.14.12 | 04:03 pm
- Affymax Announces Yearend 2011 Financial Results Teleconference And Webcast - Business Wire 03.07.12 | 04:03 pm
- Affymax To Receive $5 Million Milestone Payment For Acceptance Of European Marketing Authorization Application For Peginesatide - Business Wire 02.27.12 | 08:02 am
- Affymax Announces Upcoming Webcasts And Conference Participation - Business Wire 02.21.12 | 04:02 pm
- Affymax To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 04:02 pm
Partner Headlines for AFFY
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 05.23.12 | 09:05 am
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Cramer's Lightning Round - Danaher Has Good Blood Lines (2/10/12) - Seeking Alpha 02.12.12 | 07:02 am
- Affymax Spiking Higher on Heavy Volume - Benzinga 12.27.11 | 01:12 pm
- 7 Stocks With Unusual Options Activity - Seeking Alpha 12.09.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
